Category Archives: Industry: Healthcare

Healthcare is an ever evolving industry, and field. These Press Releases, will keep you up to date on the newest, greatest, best, solutions available.

iPatientCare to demonstrate its Telehealth, Remote Patient Monitoring and HIE connections at HIMSS 2020


iPatientCare to demonstrate its Telehealth, Remote Patient Monitoring and HIE connections at HIMSS 2020

“With the HIMSS 2020 focus on worldwide healthcare change, the conference is a wonderful opportunity for us to showcase our innovative and ever-advancing healthcare technology which has been designed to enhance healthcare outcomes.” said Udayan Mandavia, Chief Growth Officer, iPatientCare/AssureCare

iPatientCare, a pioneer in cloud-based ambulatory EHR, revenue cycle management services, integrated practice management, and patient engagement solutions announces its participation at HIMSS 2020, taking place on March 9 – 13, 2020 in Orlando, Florida. As a platinum member of HIMSS, iPatientCare has been participating in HIMSS for nearly two decades to help its customers – from small and rural health practices to hospitals and healthcare systems to navigate the changing healthcare landscape and deliver innovative solutions for providers as well as patients.

The HIMSS Global Health Conference & Exhibition brings together nearly 45,000 health information and technology professionals, clinicians, executives and market suppliers from around the world. Exceptional education, world-class speakers, cutting-edge products and powerful networking are hallmarks of this industry-leading conference.

“iPatientCare, being recognized by HIMSS as “The first recipient of the ConCert” and “One of the Health IT Industry Leader at IHE NA Connectathon” during the past HIMSS conferences, has been instrumental in driving the “change” in the healthcare ecosystem by continuously evolving its cloud-based platform to help the caregivers stay connected throughout the continuum of care,” said Kedar Mehta, Chief Technology Officer, iPatientCare/AssureCare.

“With the HIMSS 2020 focus on worldwide healthcare change, the conference will be a wonderful opportunity for us to showcase our innovative and ever-advancing healthcare technology which has been designed to enhance healthcare outcomes, improve patient experience at reduced costs. Now into our 19th consecutive year of association with HIMSS, we realize we only get stronger with every passing year. We look forward to sharing, collaborating and inspiring better health through information and technology at HIMSS 2020,” said Udayan Mandavia, Chief Growth Officer, iPatientCare/AssureCare.

Be sure to stop by Booth #359 to check out some demos, meet some clients and partners, and witness all the latest developments in iPatientCare EHR, Practice Management System, and the centralised HIE model. Or contact today at Sales@iPatientCare.com to talk to one of the IT associates to learn more about what iPatientCare can do to fulfill your healthcare technology needs.

About iPatientCare

iPatientCare is a full suite of innovative healthcare products and value-added services that help physician offices, rural health clinics, and community/federally qualified health centers (CHC/FQHC) nationwide in improving the health of their patients, enhancing patient care through care management/coordination/analytics, and reducing costs of care delivery.

The awards-winning EHR, integrated practice solutions and value-added services, such as, the revenue cycle enhancement and quality improvement consulting, provide everything you need to control your practice operations, increase revenues, and provide better patient care.

The iPatientCare EHR – version 18.0, has received 2015 Edition ONC Health IT certification by Drummond Group, an Office of the National Coordinator-Authorized Certification Body (ONC-ACB), in accordance with the applicable eligible professional certification criteria adopted by the Secretary of Health and Human Services (HHS). Full certification details can be found at the ONC Certified Health IT Product List.

As part of its MACRA-ready solutions, iPatientCare has been recognized as a qualified MACRA-MIPS registry by CMS, and has a distinguished credit of being selected as a preferred EHR and medical billing software by more than 70,000 users nationwide, numerous hospitals/health systems, federally funded regional extension centers, and in the past by the US Army and NASA Space Medicine.

Visit https://www.iPatientCare.com for more information.

Share article on social media or email:

Ziegler Closes $109 Million Series 2019 Bonds For St. Ann’s Community Project


“This project provides us the flexibility to streamline our financial strategy and remain focused on offering seniors exceptional housing and health services,” stated, Dennis P. Kant, Senior Vice President & CFO of St. Ann’s Community.

Ziegler, a specialty investment bank, is pleased to announce the successful closing of the St. Ann’s Community Project $108,825,000 Series 2019 Tax-Exempt Fixed Rate Bonds.

St. Ann’s of Greater Rochester (St. Ann’s Community) is a senior housing and health services provider that is the parent company to four residential and long-term care affiliates in the Rochester, NY area. Additionally, St. Ann’s Community partially owns and owns communities outside the Obligated Group.

St. Ann’s Community began a campus-wide master plan in 2015 to continue to reposition itself in a manner to best serve their residents. Phase I (complete) included the relocation of 34 post-acute rehabilitation beds from its Wegman Care Center to the 9th floor of St. Ann’s Home, the largest of their skilled nursing facilities. Phase II (the “Project”) will involve the renovation of St. Ann’s Home floors 3-8 and will result in a net reduction of 96 beds.

Proceeds of the Series 2019 Bonds were used by St. Ann’s Community, together with other available funds to, (1) fund costs of the Project, (2) fund Capitalized Interest, (3) refund the outstanding indebtedness of the Obligated Group, (4) fund the termination of existing swaps, (5) fund a Debt Service Reserve Fund, and (6) pay for certain costs of issuance incurred during the financing. The Series 2019 Bonds are non-rated and were issued through the Monroe County Industrial Development Corporation with an aggregate yield to maturity of 4.297% on the entire issue. Ziegler was able to secure aggressive call provisions on behalf of St. Ann’s Community, with the bonds callable in 6-years at a price of 103% declining to par in 9-years.

“This project provides us the flexibility to streamline our financial strategy and remain focused on offering seniors exceptional housing and health services,” stated, Dennis P. Kant, Senior Vice President & CFO of St. Ann’s Community. “We are well positioned in a competitive market to address changing expectations of seniors and their families, while staying committed to our mission of delivering quality care and service to the most important people on earth.”

Ziegler is one of the nation’s leading underwriters of financing for not-for-profit senior living providers. Ziegler offers creative, tailored solutions to its senior living clientele, including investment banking, financial risk management, merger and acquisition services, seed capital, FHA/HUD, capital and strategic planning as well as senior living research, education, and communication.

For more information about Ziegler, please visit us at http://www.ziegler.com.

About Ziegler:

Ziegler is a privately held, national boutique investment bank, capital markets and proprietary investments firm. We have a unique focus on healthcare, senior living and education sectors, as well as general municipal and structured finance. Headquartered in Chicago with regional and branch offices throughout the U.S., Ziegler provides its clients with capital raising, strategic advisory services, fixed income sales & trading and research. To learn more, visit http://www.ziegler.com.

Certain comments in this news release represent forward-looking statements made pursuant to the provisions of the Private Securities Litigation Reform Act of 1995. This client’s experience may not be representative of the experience of other clients, nor is it indicative of future performance or success. The forward-looking statements are subject to a number of risks and uncertainties, in particular, the overall financial health of the securities industry, the strength of the healthcare sector of the U.S. economy and the municipal securities marketplace, the ability of the Company to underwrite and distribute securities, the market value of mutual fund portfolios and separate account portfolios advised by the Company, the volume of sales by its retail brokers, the outcome of pending litigation, and the ability to attract and retain qualified employees.

Share article on social media or email:

Palette Life Sciences Launches MySolesta.com, a New Online Resource for Bowel Incontinence to Support Healthcare Professionals, Caregivers and Patients


News Image

We are confident that MySolesta.com will greatly help patients affected by bowel incontinence, as well as caregivers and the healthcare professionals treating this condition by providing them with valuable information and connecting patients and HCPs – Rich Low, Palette Life Sciences

Palette Life Sciences, Inc., today announces the launch of MySolesta.com, an online educational resource specifically designed for healthcare professionals (HCPs), caregivers, and patients suffering from bowel incontinence, also known as fecal incontinence (FI). The site provides valuable information, education and resources focused on the causes, risk factors, symptoms and treatment options for FI, including Solesta® – the quick, nonsurgical treatment for bowel incontinence.(1)

MySolesta.com empowers patients and caregivers by providing them valuable information and connects them with physicians in their area who specialize in treating bowel incontinence. In addition, the site includes information and resources pertaining to reimbursement assistance for treatments.

Bowel incontinence or fecal incontinence affects millions of people worldwide. Research indicates that up to 18% of the general population worldwide suffers from bowel incontinence.(2) However, due to the shame and emotional toll of this condition, many people avoid seeking bowel incontinence treatment so the number of cases is likely higher.(3)

Bowel incontinence can present as anal leakage of loose stool, solid stool or mucus. Such uncontrollable anal discharge, can be upsetting, embarrassing, and may discourage patients to talk with their doctor about their bowel incontinence challenges.

For physicians, the site provides simple and straightforward information on training and certification for administering Solesta; HCPs can simply follow three easy steps at MySolesta.com.

Solesta is the only FDA-approved minimally invasive treatment for bowel incontinence. It is an easily injectable, viscous gel made from two polysaccharides; Non-Animal Stabilized Hyaluronic Acid (NASHA™) and Dextranomer (Dx) microspheres. The Solesta implant is stable, remains in position, and does not disappear over time.(3,4) Solesta is the only injectable gel to be administered in an outpatient setting without the need for anesthesia.(1) Studies have shown that Solesta can help patients return to a more active lifestyle (socializing, going to work, etc.) and reduce overall depression and embarrassment associated with their bowel control problems.(5)

“For patients looking for a quick, nonsurgical fecal incontinence treatment, Solesta may be an ideal choice,” said Dr. Zuri Murell, Los Angeles based colorectal surgeon and specialist. “My patients who opted for Solesta were pleased with the results. With the launch of the new MySolesta.com website, I hope patients find comfort knowing there is an effective treatment for their condition that can improve their quality of life and that they are not alone.”

“We are confident that MySolesta.com will greatly help patients affected by bowel incontinence, as well as caregivers and the healthcare professionals treating this condition by providing them with valuable information and connecting patients and HCPs,” said Richard Low, Head of Marketing, Palette Life Sciences.

About Solesta

Solesta, a Non-Animal Stabilized Hyaluronic Acid (NASHA™) and dextranomer gel, is a tissue bulking agent that is injected into the submucosal layer of the anal canal for treatment of Bowel Incontinence in adults. It’s a minimally invasive, outpatient procedure that has been proven effective for up to 36 months. Learn more at MySolesta.com.

About Palette Life Sciences

Palette Life Sciences is focused on providing a wide range of products and services that improve the quality of life for patients. Led by experienced healthcare executives, the initial company strategy is to transform applications of existing technologies to bring forward novel solutions for underserved conditions. Palette Life Sciences, Inc. is a wholly owned subsidiary of Pharmanest AB headquartered in Stockholm, Sweden. Learn more at MySolesta.com and palettelifesciences.com.

References:

1.    Solesta [Package Insert]. Santa Barbara, CA: Palette Life Sciences.

2.    Ng K, Sivakumaran Y, Nassar N, Gladman MA. Fecal incontinence: community prevalence and associated factors–a systematic review. Dis Colon Rectum. 2015;58(12):1194-1209.

3.    Irwin T, Snow AR, Orton TS, Elliot C. Endoscopic, ultrasonographic, and histologic descriptions of dextranomer/hyaluronic acid in a case of fecal incontinence. Case Reports in Pathology. 2018.

4.    Cerwinka WH, Scherz HC, Kirsch AJ. Endoscopic treatment of vesicoureteral reflux with dextranomer/hyaluronic acid in children. Adv Urol. 2008;513854.

5.    Graf W, Mellgren KE, et al; for NASHA Dx study group. Efficacy of dextranomer in stabilised hyaluronic acid for treatment of faecal incontinence: a randomised, shame-controlled trial. Lancet. 2011;377(9770):977-1003.

APM082A

Share article on social media or email:

NeuroFlow Partners with athenahealth’s Marketplace Program to Optimize Management of Behavioral Health Data


The integration into athenaOne has been wonderful

NeuroFlow, a provider of healthcare technology and advanced analytics, today announced a partnership with athenahealth, Inc. through athenahealth’s Marketplace program. As part of the athenahealth® Marketplace, this newly integrated application is now available to athenahealth’s growing network of 160,000 healthcare providers for workflow automation and the delivery of holistic, integrated care.

Thanks to NeuroFlow’s EMR integration, athenahealth clients can seamlessly and digitally deliver validated behavioral health screeners and assessments to assist with clinical decision-making. NeuroFlow also offers many patient-facing tools coupled with incentives to encourage engagement in tracking and improving their mental wellness. “The integration into athenaOne has been wonderful,” said Dr. Sudhir Rao of Pain and Spine Specialists, a leading pain management clinic with locations in Maryland, Pennsylvania, and Virginia. “Patients enjoy the ability to pre-fill out forms on their phones prior to visits and love using the breathing techniques.”

athenahealth is a network-enabled, results-oriented services company that offers medical record, revenue cycle, patient engagement, care coordination, and population health services for hospital and ambulatory clients. The company’s vision is to build a thriving ecosystem that delivers accessible, high-quality, and sustainable healthcare for all. As a Marketplace partner, NeuroFlow joins a network of like-minded healthcare professionals who are looking to disrupt established approaches in healthcare that simply aren’t working, aren’t good enough, or aren’t advancing the industry and help providers thrive in the face of industry change.

Patient-generated activity from the NeuroFlow app such as mood and sleep trackers, pain logs, journal entries, breathing exercises, and more are automatically placed in the patient’s chart as a summary report to help monitor patient progress and trends at a glance. The tools, assessments, and mental wellness resources provided to patients also support many reimbursable codes — including several that do not require in-office visits. To learn more about NeuroFlow’s new integrated application, please visit the product listing page on the Marketplace.

About NeuroFlow

NeuroFlow is a collaborative and measurement-based behavioral health platform integrated in all care settings. NeuroFlow’s suite of HIPAA-compliant, cloud-based tools simplify remote patient monitoring, improve risk stratification, and facilitate collaborative care. Hundreds of health systems, clinicians, and care teams are using NeuroFlow to bridge the gap between mental and physical health in order to improve patient outcomes and reduce the cost of care. Learn more at http://www.neuroflowsolution.com

About athenahealth Marketplace

The athenahealth Marketplace, the largest EMR app store, is where athenahealth customers find innovative healthcare IT solutions that extend athenahealth services and allow customers to create highly tailored user experiences. Customers use Marketplace partner solutions to boost practice efficiency, increase patient satisfaction, and engage patients in their own care. The Marketplace has more than 250 solutions across 60 categories that are seamlessly integrated with athenaNet, athenahealth’s network-enabled platform through which the company offers medical records, revenue cycle, patient engagement, and care coordination service offerings.

Share article on social media or email:

Emergo by UL launches 510(k) Builder for streamlined US FDA medical device submissions


News Image

Emergo by UL’s 510(k) Builder has been developed to help medical device manufacturers achieve US FDA clearance more cost-effectively and faster.

Emergo by UL, a global medical device and healthcare technology consultancy, has rolled out 510(k) Builder, a new subscription-based software tool to simplify and streamline medical device manufacturers’ FDA 510(k) submissions in order to obtain faster US market access.

Available through Emergo by UL’s Regulatory Affairs Management Suite (RAMS) automated medical device registration and compliance platform, 510(k) Builder provides step-by-step support for preparing and compiling a complete Premarket Notification submission according to FDA requirements.

Key features of 510(k) Builder include:


  • Full integration with FDA databases, allowing users to quickly identify product codes, predicate devices and relevant standards;
  • A “token system” providing auto-population capabilities to ensure consistent application of content throughout a 510(k) premarket submission;
  • Commenting and feedback tools to enable collaboration among staff as the 510(k) is assembled;
  • Automated formatting to meet FDA specifications and reduce submission production time.

FDA 510(k) submission generation typically involves manual preparation and compiling of hundreds of documents; oversights and errors can result in delayed clearance and increased market entry costs for device manufacturers.

“Inconsistencies and omissions in 510(k) premarket submissions can lead to substantial delays for US market applicants, especially when these errors pertain to Indications for Use, product name and related data,” explains Elizabeth Manning, Program Manager at Emergo by UL. “We’ve developed 510(k) Builder to help medical device manufacturers realize more efficient submission generation, plus reduce costly delays in obtaining 510(k) clearance.”

About RAMS

Emergo by UL’s Regulatory Affairs Management Suite (RAMS) software service provides digital tools and insights to help medical device manufacturers monitor regulatory changes, efficiently and cost-effectively prepare FDA 510(k) submissions, and manage device registrations and renewals. Learn more about our automated RA/QA platform at EMERGObyUL.com/RAMS.

About Emergo by UL

EMERGO by UL is a leading regulatory consulting firm specializing in global medical device and IVD compliance. Our comprehensive solution is designed to help you achieve and maintain regulatory and commercial success. With a presence on six continents, we can provide real-time service and on-the-ground expertise. Learn more about how we can help you grow at EMERGObyUL.com.

Share article on social media or email:

Understand.com® & Blausen Medical Announce Partnership


Understand.com and Blausen Medical announced their global partnership today. These two leaders in medical animation have combined their extensive medical content offerings with Understand.com serving as the sales and marketing arm for both companies.

“I have admired the quality and breadth of Blausen’s medical animations for many years,” said Darik Volpa, founder and CEO of Understand.com. “This partnership represents thousands of hours of hard work at both companies. From our new website to our new video player, this launch will position us as the number one site for doctors and hospitals interested in medical education content for their patient education needs.”

“We at Blausen are pleased to announce our partnership with Understand.com,” said Bruce Blausen, founder and CEO of Blausen Medical. “They are an incredible organization with superb sales and marketing capabilities. Understand.com has the corporate leadership necessary to bring our collective content to the largest number of buyers. We could not be more pleased.”

Medical libraries are now offered in the following specialties:

  • Plastic Surgery
  • Ophthalmology
  • Diabetes
  • Oncology
  • Orthopedics
  • Dental
  • OBGYN
  • Gynecology Oncology
  • Spine
  • Ear, Nose, & Throat
  • Maternal-Fetal     
  • Hepatology Oncology
  • Dermatology    
  • Respiratory System    
  • Male Reproduction    
  • Radiology
  • Breast Cancer    
  • Cardiovascular System     
  • Urology     
  • Radiation Oncology
  • Hair    
  • Digestive System    
  • Immunology    
  • Diagnostic Radiology
  • Neurology
  • Bariatric     
  • Allergy
  • Pharmacology

Languages include English (US and Great Britain), French, German, Arabic, Chinese (Cantonese and Mandarin), Dutch, Danish, Hungarian, Italian, Japanese, Korean, Norwegian, Portuguese (Brazil and Portugal), Romanian, Russian, Spanish (Latin American and Castilian), Turkish and Swedish.

In addition to the expanded content offering, animations now can be licensed individually and customers have the ability to create their own libraries based on their specific practice needs.

About Understand.com

Founded in 2003, Understand.com® is a global medical education company that has educated over 10,000,000 patients worldwide. Their unparalleled 3D medical animations are at the core of the patient learning experience. Their content clearly explains complex MOAs, disease pathologies, surgical techniques and procedures, as well as treatment methods for hundreds of medical topics.

Understand.com recognizes the huge gap in communication between doctors and patients. Doctors are frequently overloaded with patients, and may lack the time or skills to effectively communicate the complexity of a medical condition or procedure to their patients. Consultations can leave patients confused, frustrated, and unable to get the information they need to be active participants in their own medical care. Understand.com viewed this challenge as an opportunity to empower doctors and educate patients by providing high-quality, informative patient education content.

About Blausen Medical

Founded in 1991, Houston-based Blausen Medical Communications, Inc., is the developer, owner and licensor of the world’s largest library of 3D medical animations. Known for their high standard of excellence in scientific and medical accuracy, Blausen creates masterpieces that explain difficult concepts with exceptional clarity.

Blausen Medical’s extensive library content is available for multiple platforms. The award-winning animation library is now viewed in every country in the world and has been translated into over 21 languages. The company and its products have received over 30 honors, including the 2013 Platinum Award for Best Interactive Site; and the Gold Award for Best Mobile Communications in eHealthcare Leadership. Blausen Medical has also been honored with numerous Web Health Awards, and with an ABBY Award from the Adaptive Business Leaders Organization for developing innovations that reduce the cost of quality healthcare.

Share article on social media or email:

Clinerion and Datametrix Partner to Deliver Real World Evidence (RWE) Insights from Real World Data (RWD) from Clinerion’s Global Hospital Network


Together, Clinerion and Datametrix will power Real World Evidence (RWE) research and bring insights on the realities of clinical practice and outcomes. They will enable Real World Data (RWD) research to investigate differential treatment outcomes in support of optimizing care protocols. This is acutely relevant for field-leading clinicians, hospital management and health policy makers.

Following recent FDA guidance calls for more use of RWD to balance the need for randomized controlled studies, biopharma customers can leverage RWE to inform development strategies, help make development decisions and limit the number of costly, full-scale prospective randomized controlled clinical studies. RWE research can also be used to investigate actual patient pathways and give useful insights to determine better, more effective approaches to care.

The synergy that follows from the combination of Clinerion’s RWD and Datametrix’s analytical capabilities supports pharmaceutical companies with optimization of clinical study design to meet strategic development needs while reflecting real patient populations, where the patients are. It helps pharma customers drive successful recruitment by being able to select sites that see a sufficiently large population of potentially eligible patients; and then also helping those sites directly identify the eligible patients. It also enables improvement in the accuracy of RWD comparative clinical studies by applying statistical models to define the RWD study end points. Clinerion can use their access to RWD data to recruit patient to RWD comparative arms.

“We believe that data collected in an organized and simple manner, then analyzed using the right analytical tools will empower pharmaceutical and biotechnology companies to bring better drugs to market faster,” says Ahmed El Rhali, CEO of Datametrix. “Together, Datametrix and Clinerion can power Real World Evidence research and bring insights in the realities of clinical practice, which is acutely relevant for pharmaceutical industry, field-leading clinicians, hospital management, healthcare policy makers and, of course, patients.”

“Clinerion and Datametrix are acutely aware that clinical trials are becoming more complex.” says Léon Van Wouwe, Site & Patient Network Director, Clinerion. “And despite global technological advances, the time to get new treatment options to patients and the associated costs are going up. We need to reimagine how pharma sponsors, CROs, investigators and patients engage with another and collaborate to drive successful trial design & delivery. This partnership presents an ‘integrated clinical research offer,’ in which patients, investigators, research sites, pharma and other service providers integrate efforts to unite around one single purpose: to bring together all patients with all the available treatment options that may suit them, and so improve patient outcomes.”

About Clinerion

Clinerion accelerates clinical research and medical access to treatments for patients. We use proprietary technologies for analysis of patient data from our global network of partner hospitals. Clinerion’s Patient Network Explorer radically improves the efficiency and effectiveness of clinical trial recruitment by offering data-driven protocol optimization, site feasibility evaluation and real-time patient search and identification to match patients to treatments. Our technology solution provides real-world evidence analytics for medical access. Clinerion facilitates the participation of partner hospitals in leading-edge, industry-sponsored trials and time savings in patient recruitment. We create innovative and disruptive fit-for-purpose solutions which enable pharmaceutical companies to shorten patient recruitment and save costs by streamlining operations and leveraging strategic intelligence. Clinerion’s proprietary Big Data analytics technologies leverage real-time data from electronic health records which comply with international patient privacy and data security regulations. Clinerion is a global data technology service company headquartered in Switzerland.

Clinerion website: http://www.clinerion.com

Clinerion’s Patient Network Explorer: http://www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

For more information, please contact:

Le Vin Chin

Director, Head of Marketing & Communications

Clinerion Ltd

Elisabethenanlage 11, 4051 Basel, Switzerland

Tel.: +41 61 865 60 54

media@clinerion.com

About Datametrix AG

Datametrix AG is a Swiss data analysis company founded in 2003. We close the gap between data and information by bridging science together with data, advanced analytics and expert knowledge to deliver beyond expected results! We shape our services around customers’ business needs to offer them the different way forward in four main area of our expertise:

1. Data analysis, including RWD and RWE

2. Biostatistical analysis

3. HEOR modelling

4. Data management

Unlock your data potential, with the possibility to supplement the primary data collection points with real world insights, choose simple and problem loss data analysis solutions, solid expert knowledge and customer oriented approach.

Datametrix website: http://www.datametrix.ch

For more information, please contact:

Ahmed El Rhali

CEO

Datametrix AG

Faubourg de l’Hopital 3, Neuchâtel, Switzerland

Tel.: +41 32 511 4575

ahmed@datametrix.ch

Irina El-Ali

COO

Datametrix AG

Faubourg de l’Hopital 3, Neuchâtel, Switzerland

Tel.: +41 32 511 4575

Mobile: +41 79 212 7199

irina.el-ali@datametrix.ch

Share article on social media or email:

Living liver donors generously swap, saving 2 recipients


Taranjeet Klair, M.D., Long School of Medicine

Tarunjeet Klair, M.D., of the Long School of Medicine at The University of Texas Health Science Center at San Antonio, treats University Transplant Center patients at University Hospital.

“For a healthy person to come and go through this for somebody else is not an easy thing.” – Tarunjeet Klair, M.D., assistant professor of surgery in the Long School of Medicine at The University of Texas Health Science Center at San Antonio and surgical director of the Living Liver Donor Program

A major emphasis by the American Society of Transplant Surgeons is to increase organ donation in order to save the lives of patients suffering from end-stage organ failure. Currently an estimated 15% of patients die while on the waiting list in the United States because there are insufficient organs to meet this lifesaving demand. Decreasing the waiting list mortality requires more organs being procured from both deceased and living donors, which in turn requires innovation and organ preservation research. In San Antonio, Texas, transplant surgeons at the Long School of Medicine of The University of Texas Health Science Center at San Antonio innovated an effective approach to maximize the altruistic desire and contributions of living liver donors.

A conundrum last April

Anna Moreno hoped to donate part of her liver to save her father, Mark Blair. Natasha Sanchez felt led by God to give part of her liver to her friend, Sarah D’Angelo. Then the tests came in. Anna wasn’t a match for her father. Natasha, however, was a match for both D’Angelo and Blair.

What to do? Anna Moreno and Natasha Sanchez had both prepared to be living liver donors at University Transplant Center, a clinical partnership combining the excellence of physicians in the Long School of Medicine with the technology and support teams of University Health System.

Tarunjeet Klair, M.D., assistant professor of surgery in the Long School of Medicine and surgical director of the Living Liver Donor Program, suggested an alternative – swap donors so that both recipients could receive a transplant.

On two days in April 2019, the transplant team performed the transplants that saved Mark Blair and Sarah D’Angelo. Recovery progressed, and the following October, University Transplant Center welcomed the recipients and donors for a reunion of themselves and members of the transplant team.

The paired exchange was the first in the U.S. for living liver transplants, as far as the transplant center’s program directors are aware. The team performed a second paired exchange in July.

Living liver programs are rare

University Transplant Center is among only three dozen transplant centers nationwide – including three in Texas – that perform living liver transplants. In both 2018 and 2019, the transplant center was the second largest program in the United States in the number of living liver transplants.

Many centers do not have experience with living liver donors, and paired exchanges require specialized surgical training and expertise. “Given the large volume of very successful living donor transplant cases managed by our team, who also perform a large number of complex liver resections annually to remove cancers and other lesions in the liver, our center knew we had the safety record, standards and expert team members in place to save more patients through paired exchange,” Dr. Klair said.

Success in living donor liver transplantation requires four highly trained surgeons and a robust team of professionals including transplant hepatologists, nutritionists, nurses and social workers, to name a few. University Transplant Center comprises a cadre of professionals who follow the patients through their journeys from illness to recovery. Many team members, as faculty of the Long School of Medicine, are involved in transplant research and health professional education.

The recent success with living donors is built upon a strong foundation of deceased donor liver transplantation over three decades and a comprehensive and talented team. Glenn A. Halff, M.D., professor of surgery in the Long School of Medicine, inaugurated the liver transplant program in 1993, and within five years the transplant center was performing more than 100 liver transplants a year, far exceeding expectations.

Shortening the waiting list

Long School of Medicine pediatric and transplant surgeon Francisco G. Cigarroa, M.D., who directs University Transplant Center, joins Dr. Halff, Dr. Klair and the entire team in promoting living liver donation as a long-term solution for the shortage of deceased donors. A transplant center needs to develop a broad culture of advocating for living donation and associated comprehensive education for interested living donors. Late last year, almost 13,000 people were on the national liver transplant wait list, including nearly 1,400 in Texas.

“We strive to shorten the waiting list to transplantation through multiple innovative approaches including living donor liver transplants,” Dr. Cigarroa said.

The liver is the largest organ in the body. Among its many functions, it secretes bile, which aids digestion. Because the liver possesses the amazing ability to regrow, surgeons may remove a portion of the liver of a healthy individual to transplant into a person whose liver is diseased. Within a couple of months, the donor’s remaining liver regrows to a normal size, while the portion of liver transplanted into the recipient also grows and restores healthy liver function.

This is a lifesaver for recipients who need a liver transplant due to cancer, cirrhosis (scarring) or other disease. They can avoid having to become very sick while waiting for a matching liver from a deceased donor. It is a wait that unfortunately some patients don’t survive.

Surgeon’s vision

The innovation of paired exchanges ensures compatibility of living liver donations between well-prepared donors and waiting recipients. Dr. Klair’s inspiration made it happen.

“Dr. Klair has an unrelenting commitment to the safety and well-being of our patients, and where donor supply falls short, he is always looking for a solution to bridge the gap and make sure that we can give a safe alternative to our patients,” said Jennifer Milton, RN, chief administrative officer of University Transplant Center.

Accordingly, the center increased living liver transplants from six in 2017 to 39 in 2019.

The living liver paired exchange also requires patients and families to trust their medical providers. “For a healthy person – who doesn’t need an operation – to come and go through this for somebody else is not an easy thing,” Dr. Klair said. “We recognize that.”

Mark Blair and Sarah D’Angelo, with a new lease on life thanks to their “liver buddies” Natasha Sanchez and Anna Moreno, are among the grateful beneficiaries.

The Long School of Medicine at The University of Texas Health Science Center at San Antonio is named for Texas philanthropists Joe R. and Teresa Lozano Long. The school is the largest educator of physicians in South Texas, many of whom remain in San Antonio and the region to practice medicine. The school teaches more than 900 students and trains 800 residents each year. As a beacon of multicultural sensitivity, the school annually exceeds the national medical school average of Hispanic students enrolled. The school’s clinical practice is the largest multidisciplinary medical group in South Texas with 850 physicians in more than 100 specialties. The school has a highly productive research enterprise where world leaders in Alzheimer’s disease, diabetes, cancer, aging, heart disease, kidney disease and many other fields are translating molecular discoveries into new therapies. The Long School of Medicine is home to a National Cancer Institute-designated cancer center known for prolific clinical trials and drug development programs, as well as a world-renowned center for aging and related diseases.

The University of Texas Health Science Center at San Antonio, dba UT Health San Antonio, is one of the country’s leading health sciences universities and is designated as a Hispanic-Serving Institution by the U.S. Department of Education. With missions of teaching, research, healing and community engagement, its schools of medicine, nursing, dentistry, health professions and graduate biomedical sciences have graduated more than 37,000 alumni who are leading change, advancing their fields, and renewing hope for patients and their families throughout South Texas and the world. To learn about the many ways “We make lives better®,” visit http://www.uthscsa.edu.

Stay connected with The University of Texas Health Science Center at San Antonio on Facebook, Twitter, LinkedIn, Instagram and YouTube.



New Everest Rehabilitation Hospital Holds Ribbon Cutting Ceremony in Northwest Arkansas


Everest Rehabilitation Hospitals

We are so excited to provide our ultra-quality rehabilitation care to the citizens of Northwest Arkansas

Today, after nearly two years of planning and construction, Everest Rehabilitation Hospitals, NWA, LLC is cutting the ribbon on its newest, modern, state-of-the art, physical rehabilitation hospital in Rogers, Arkansas. Everest’s comprehensive rehabilitation hospital is centrally located for the entire Northwest Arkansas population to benefit. The rehabilitation hospital is located just a block east of Interstate 49 at the corner of South Pleasant Crossing and South Dixieland Road (4313 S. Pleasant Crossing Blvd, Rogers AR).

Everest’s Rehabilitation Hospital includes:

  • 41,000 square feet of a modern, naturally sunlit design to enhance our patient and staff experience.
  • 36 private rooms with the predesigned ability to expand the hospital by another 18 rooms in the future.
  • 2 large, modern equipped, Inpatient and Outpatient Therapy Gyms.
  • A complete, licensed pharmacy and in-house dialysis.
  • A Therapy Car for mobility therapy.
  • A large therapy courtyard with a multitude of therapy options.
  • A HydroWorks pool/treadmill with water jets to create buoyancy for low impact resistance therapy.
  • A fully furnished Assisted Daily Living apartment with Kitchen and Bath.
  • A large dining hall with a patio for patients, physicians, staff and family to enjoy.
  • A multitude of family gathering and meeting areas.

Jay Quintana, Everest Rehabilitation’s CEO said, “We are so excited to provide our ultra-quality rehabilitation care to the citizens of Northwest Arkansas! We provide one to one, physical therapy care to our patients, five to seven days a week. We have a very strong nurse patient ratio that contributes to optimal outcomes in our modern, naturally lit hospitals. Our enormous level of care in our acute rehabilitation hospital setting cannot be provided at other levels of care such as skilled nursing facilities or nursing homes.”

Everest Rehabilitation Hospital’s physical therapy programs are led by physicians and staff specifically trained in medical rehabilitation and provide for around the clock registered nursing care to patients overcoming a stroke, brain injury, neurological deficits, orthopedic conditions, pulmonary disease, spinal cord injury, amputations and other medically complex conditions.

About Everest Rehabilitation Hospitals, LLC

Everest Rehabilitation Hospitals LLC, based in Dallas, Texas, is a multispecialty acute care physical rehabilitation hospital company focused on providing high quality, physical rehabilitation care. Everest is passionate about patient care; striving to create healing and nurturing environments for all patients that not only meet their medical needs but address their emotional and social needs as well. Patients are guided through the necessary steps to reclaim daily life, recover function, and return to an optimal quality of life by combining the latest treatments, technologies, and research with a unique interdisciplinary team approach involving the patient and family from day one. Everest provides the highest level of care available to patients with disabilities caused by injuries or illnesses, or from traumatic accidents.

http://www.everestrehab.com

Jay Quintana, CEO/ Co-Founder

Jquintana(at)everestrehab.com

469-713-1145

Share article on social media or email:

StudyKIK Launches Patient Oriented Direct Scheduling Service with Transportation Concierge for Clinical Trials


patient no show rates have dropped by over 65% and, in turn, consent and randomization rates have significantly grown since launch.

StudyKIK, a patient recruitment and retention technology company, announced a new platform that will simplify entry into clinical trials for patients. The new interface will give StudyKIK the ability to directly schedule patients for over 3,600 research sites and support the required study visits through their Patient Transportation Concierge service. Developed to enhance the overall patient experience and decrease no-show rates, this new service offering is now available for all clinical trials being supported by StudyKIK for patient recruitment.

These developments were made possible due to advancements within StudyKIK’s in-house patient qualification call center and technology platform. With this innovative capability, StudyKIK can reduce the burden on research sites by identifying unqualified patients earlier in the process and facilitating the entrance of qualified patients into the respective study.

A major industry problem that takes place during clinical trial patient recruitment is when recruitment companies refer a large number of unqualified patients to research sites, which can lead to frustration and study fatigue for site staff. Following up with referrals for study visit scheduling can be a challenge in itself, since 82% of people do not answer phone calls from unknown phone numbers, thus making outreach time-consuming and oftentimes futile.

With StudyKIK’s pre-screening service, the patient is already on the phone with an agent at the time of pre-qualification, and the new direct scheduling feature allows each agent to preview the research site’s availability and set an appointment immediately, without ever having to interrupt the site’s workflow.

Additionally, StudyKIK offers transportation as a patient-centric convenience and means to increase study visit attendance. In providing these services, patient no show rates have dropped by over 65% and, in turn, consent and randomization rates have significantly grown since launch.

StudyKIK’s Chief Operating Officer, Brian Kay, states,”Three out of four referrals that sign up have never participated in a clinical trial before; StudyKIK’s pre-screening process not only helps identify potentially qualified patients, but also starts the trust-building process with each referral. If patients are told by sites immediately after pre-screening that they will not be reimbursed for their time or travel expenses for the initial visit if they don’t qualify, that patient is likely to no-show. From their perspective, this process can sound like a scam, which is precisely why the industry is seeing a 50% no-show rate in many cases. By taking over the logistics and covering the transportation costs, StudyKIK’s direct scheduling service clears the bureaucratic and financial obstacles that patients may worry about, reducing site no-show rates.”

Due to so many research sites utilizing StudyKIK’s recruitment platform to support their clinical trials, these new services will expedite the enrollment process across studies. Participating sites will receive pre-qualified patients directly on their calendars, and with confidence that the study visits will actually occur since transportation will be provided.

Every pharmaceutical company that is overseeing enrollment will be able to receive real-time confirmation of patients coming for their study visits – this could really shorten timelines and help meet enrollment targets.

More About StudyKIK:

StudyKIK is a patient recruitment and technology platform that utilizes patient communities across all major social media channels to increase awareness and connection to clinical trials. Furthermore, StudyKIK mitigates patient recruitment problems by building the technology solutions needed for research sites and pharmaceutical companies to access, manage, and communicate with high-quality patients in real-time.

To learn more about our services and technology solutions, visit StudyKIK.com or call 877-627-2509.

Share article on social media or email: